Oral bioavailability of pharmacologically effective drugs is often limited by first-pass
biotransformation. In humans, both hepatic and intestinal enzymes can catalyze the metabolism of a …

Cytochrome P4501A2 (CYP1A2) has been identified as a key factor in the metabolic
activation of numerous chemical carcinogens, including afiatoxin B1, various heterocyclic and …

Cytochrome P450 3A (CYP3A) metabolizes a diverse array of clinically important drugs. For
some of these (eg, cyclosporine, verapamil, midazolam), CYP3A in the intestinal mucosa …

Objective To provide an update on key safety metrics after transfusion of convalescent plasma
in hospitalized coronavirus 2019 (COVID-19) patients, having previously demonstrated …

BACKGROUND Convalescent plasma is the only antibody-based therapy currently available
for patients with coronavirus disease 2019 (COVID-19). It has robust historical precedence …

Previous kinetic studies have identified a high-affinity (S)-warfarin 7-hydroxylase present in
human liver microsomes which appears to be responsible for the termination of warfarin’s …

Objective To determine in humans the relative roles of intestinal and hepatic metabolism in
the oral first‐pass elimination of a CYP3A substrate using midazolam as a model compound. …

The in vivo intestinal metabolism of the CYP3A probe midazolam to its principal metabolite,
1′‐hydroxymidazolam, was investigated during surgery in 10 liver transplant recipients. …

Objective To examine the association of COVID-19 convalescent plasma transfusion with
mortality and the differences between subgroups in hospitalized patients with COVID-19. …

Background Convalescent plasma has been widely used to treat coronavirus disease 2019 (Covid-19)
under the presumption that such plasma contains potentially therapeutic …